Atopic Dermatitis
Conditions
Brief summary
This pilot study will evaluate new methods for the collection, storage, shipment, and RNA extraction of skin tape specimens from children with atopic dermatitis (AD) that will facilitate the multi-center SunBeam Birth Cohort study. Additionally, this pilot study will test new methods for the generation of whole transcriptome sequencing data from skin tape RNA and whether these data reflect the transcriptional state of the skin in health and disease.
Interventions
OTHERSkin tape strips
Skin tape strips will be collected from lesional and non-lesional skin. Adhesive skin sampling discs will be firmly pressed against the skin in a hairless location (not the face) followed by lifting it free of the skin. These discs will then be used to evaluate proteins and lipids in the upper layers of skin.
Sponsors
National Jewish Health
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
4 Years to 12 Years
Healthy volunteers
Yes
Inclusion criteria
1. Able to provide informed consent/assent. 2. Male or female, 4-12 years of age (prepuberty) inclusive at the time of consenting 3. Participant must be either: 1. Active atopic dermatitis with two areas of non-lesional AD within 5 cm of the measured lesional area within the same region. OR 2. .No personal history or current manifestations of AD, food allergy, asthma, allergic rhinitis, and no positive prick or blood testing for allergen (based on self-report); and no evidence of dry skin or other skin condition
Exclusion criteria
1. Unable to provide consent or comply with the protocol 2. Presence of any skin condition that might compromise the stratum corneum barrier in infants and young children (e.g., ichthyosis, psoriasis, extensive seborrheic dermatitis, scabies) 3. History of any skin reaction to tape, or adhesives 4. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study. 5. Use of any topical product (e.g., emollient, topical corticosteroids, topical immunomodulatory agents, topical antibiotics) on the area(s) to be tested within 24 hours before the study visit.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| skin RNA sequence for (lesional (L) and non-lesional (NL)) Skin Tape Strips (STS) | through study completion, single visit with an average of 2 hours | the novel skin tape transcriptome method will extract RNA; the outcome is to identify the difference in RNA sequence between lesional and non-lesional skin. |
Countries
United States
Outcome results
None listed